Definition of kidney dysfunction as a cardiovascular risk factor: use of urinary albumin excretion and estimated glomerular filtration rate.

PubWeight™: 1.28‹?› | Rank: Top 10%

🔗 View Article (PMID 18362254)

Published in Arch Intern Med on March 24, 2008

Authors

Massimo Cirillo1, Maria Paola Lanti, Alessandro Menotti, Martino Laurenzi, Mario Mancini, Alberto Zanchetti, Natale G De Santo

Author Affiliations

1: Unit of Nephrology, Second University of Naples, Naples, Italy. massimo.cirillo@unina2.it

Articles citing this

Age and association of kidney measures with mortality and end-stage renal disease. JAMA (2012) 7.20

Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rate. JAMA (2012) 6.26

Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol (2009) 4.43

Cystatin C, albuminuria, and mortality among older adults with diabetes. Diabetes Care (2009) 1.74

Albuminuria, impaired kidney function and cardiovascular outcomes or mortality in the elderly. Nephrol Dial Transplant (2009) 1.20

Kidney function and the risk of cardiovascular disease in patients with type 2 diabetes. Kidney Int (2013) 0.98

Estimated GFR and incident cardiovascular disease events in American Indians: the Strong Heart Study. Am J Kidney Dis (2012) 0.92

Comparison of estimated glomerular filtration rates and albuminuria in predicting risk of coronary heart disease in a population with high prevalence of diabetes mellitus and renal disease. Am J Cardiol (2011) 0.91

Relative risks of chronic kidney disease for mortality and end-stage renal disease across races are similar. Kidney Int (2014) 0.88

Cohort profile: The Gubbio Population Study. Int J Epidemiol (2013) 0.82

Kidney function and estimated vascular risk in patients with primary dyslipidemia. Open Cardiovasc Med J (2009) 0.79

Clinical correlates of renal dysfunction in hypertensive patients without cardiovascular complications: the REDHY study. J Hum Hypertens (2010) 0.77

Age- and Gender-Normalized Coronary Incidence and Mortality Risks in Primary and Secondary Prevention. Cardiol Res (2012) 0.76

Cystatin C, creatinine, and albuminuria: bringing risk into 3 dimensions. Am J Kidney Dis (2012) 0.75

Association between metabolic syndrome and premicroalbuminuria among Iranian women with Polycystic Ovary Syndrome: a case control study. Glob J Health Sci (2012) 0.75

Articles by these authors

2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens (2007) 20.09

2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens (2013) 18.17

Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet (2009) 13.64

2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2013) 12.73

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet (2004) 11.13

Mediterranean diet, lifestyle factors, and 10-year mortality in elderly European men and women: the HALE project. JAMA (2004) 9.55

2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2007) 9.43

Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet (2012) 5.81

The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens (2003) 4.91

Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens (2009) 4.87

2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens (2007) 4.59

European Society of Hypertension position paper on ambulatory blood pressure monitoring. J Hypertens (2013) 4.28

Association of overweight with increased risk of coronary heart disease partly independent of blood pressure and cholesterol levels: a meta-analysis of 21 cohort studies including more than 300 000 persons. Arch Intern Med (2007) 3.97

Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA (2003) 3.71

European Society of Hypertension guidelines for blood pressure monitoring at home: a summary report of the Second International Consensus Conference on Home Blood Pressure Monitoring. J Hypertens (2008) 3.32

The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients. J Hypertens (2005) 3.27

Management of high blood pressure in children and adolescents: recommendations of the European Society of Hypertension. J Hypertens (2009) 3.13

Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet (2004) 2.78

Metabolic syndrome in the Pressioni Arteriose Monitorate E Loro Associazioni (PAMELA) study: daily life blood pressure, cardiac damage, and prognosis. Hypertension (2006) 2.65

2013 ESH/ESC Practice Guidelines for the Management of Arterial Hypertension. Blood Press (2013) 2.62

Folate treatment and unbalanced methylation and changes of allelic expression induced by hyperhomocysteinaemia in patients with uraemia. Lancet (2003) 2.39

Genome-wide association study of blood pressure extremes identifies variant near UMOD associated with hypertension. PLoS Genet (2010) 2.24

Visit-to-visit blood pressure variability, carotid atherosclerosis, and cardiovascular events in the European Lacidipine Study on Atherosclerosis. Circulation (2012) 2.21

Estimating glomerular filtration rate: Cockcroft-Gault and Modification of Diet in Renal Disease formulas compared to renal inulin clearance. Clin J Am Soc Nephrol (2009) 2.12

Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Blood Press (2009) 1.98

Effects of immediate versus delayed antihypertensive therapy on outcome in the Systolic Hypertension in Europe Trial. J Hypertens (2004) 1.87

2007 ESH-ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Blood Press (2007) 1.76

Aspirin is beneficial in hypertensive patients with chronic kidney disease: a post-hoc subgroup analysis of a randomized controlled trial. J Am Coll Cardiol (2010) 1.74

Tolerability of long-term treatment with lercanidipine versus amlodipine and lacidipine in elderly hypertensives. Am J Hypertens (2002) 1.74

The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapy. Hypertension (2006) 1.71

Retracted The relation between pulse pressure and cardiovascular mortality in 12,763 middle-aged men from various parts of the world: a 25-year follow-up of the seven countries study. Arch Intern Med (2005) 1.68

Riskard 2005. New tools for prediction of cardiovascular disease risk derived from Italian population studies. Nutr Metab Cardiovasc Dis (2005) 1.65

Prediction of cardiovascular outcome by estimated glomerular filtration rate and estimated creatinine clearance in the high-risk hypertension population of the VALUE trial. J Hypertens (2007) 1.59

European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring. J Hypertens (2014) 1.58

Effects of past and recent blood pressure and cholesterol level on coronary heart disease and stroke mortality, accounting for measurement error. Am J Epidemiol (2006) 1.57

Studies on left ventricular hypertrophy regression in arterial hypertension: a clear message for the clinician? Am J Hypertens (2008) 1.55

Statins, antihypertensive treatment, and blood pressure control in clinic and over 24 hours: evidence from PHYLLIS randomised double blind trial. BMJ (2010) 1.53

Relationship of gender, age, and body mass index to errors in predicted kidney function. Nephrol Dial Transplant (2005) 1.52

Association of central and peripheral pulse pressure with intermediate cardiovascular phenotypes. J Hypertens (2012) 1.49

Differences between office and ambulatory blood pressures in children and adolescents attending a hospital hypertension clinic. J Hypertens (2013) 1.49

Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy. J Hypertens (2002) 1.49

Cardiovascular risk stratification according to the 2003 ESH-ESC guidelines in uncomplicated patients with essential hypertension: comparison with the 1999 WHO/ISH guidelines criteria. Blood Press (2004) 1.48

Effect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes: Study on COgnition and Prognosis in the Elderly (SCOPE). Am J Hypertens (2005) 1.47

Indexation criteria of ventricular mass and predictive role of blood pressure and body composition. Am J Hypertens (2005) 1.46

Relationships of different types of event to cardiovascular death in trials of antihypertensive treatment: an aid to definition of total cardiovascular disease risk in hypertension. J Hypertens (2014) 1.44

Prevention of coronary heart disease by diet and lifestyle: evidence from prospective cross-cultural, cohort, and intervention studies. Circulation (2002) 1.43

Assessment of long-term antihypertensive treatment by clinic and ambulatory blood pressure: data from the European Lacidipine Study on Atherosclerosis. J Hypertens (2007) 1.42

The effects of blood pressure reduction and of different blood pressure-lowering regimens on major cardiovascular events according to baseline blood pressure: meta-analysis of randomized trials. J Hypertens (2011) 1.41

Role of echocardiography and carotid ultrasonography in stratifying risk in patients with essential hypertension: the Assessment of Prognostic Risk Observational Survey. J Hypertens (2002) 1.41

Influence of high cardiovascular risk in asymptomatic people on the duration and cost of sick leave: results of the ICARIA study. Eur Heart J (2013) 1.37

Cardiovascular outcomes in hypertensive patients: comparing single-agent therapy with combination therapy. J Hypertens (2012) 1.32

Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial. J Hypertens (2008) 1.29

Re-evaluating the Rose approach: comparative benefits of the population and high-risk preventive strategies. Eur J Cardiovasc Prev Rehabil (2009) 1.28

How much does HDL cholesterol add to risk estimation? A report from the SCORE Investigators. Eur J Cardiovasc Prev Rehabil (2009) 1.28

Baseline Characteristics and Early Blood Pressure Control in the CONVINCE Trial. Hypertension (2001) 1.26

Low muscular mass and overestimation of microalbuminuria by urinary albumin/creatinine ratio. Hypertension (2005) 1.25

High incidence of benign testicular neoplasms diagnosed by ultrasound. J Urol (2003) 1.23

Is a systolic blood pressure target <140 mmHg indicated in all hypertensives? Subgroup analyses of findings from the randomized FEVER trial. Eur Heart J (2011) 1.23

Age, renal tubular phosphate reabsorption, and serum phosphate levels in adults. N Engl J Med (2008) 1.20

Detection of testicular ultrasonographic lesions in severe male infertility. J Urol (2004) 1.18

New-onset diabetes and antihypertensive drugs. J Hypertens (2006) 1.18

International Society of Hypertension (ISH): statement on the management of blood pressure in acute stroke. J Hypertens (2003) 1.14

Metabolic syndrome and target organ damage in untreated essential hypertensives. J Hypertens (2004) 1.13

Systolic vs diastolic blood pressure control in the hypertensive patients of the PAMELA population. Pressioni Arteriose Monitorate E Loro Associazioni. Arch Intern Med (2002) 1.11

Prevalence of home blood pressure measurement among selected hypertensive patients: results of a multicenter survey from six hospital outpatient hypertension clinics in Italy. Blood Press (2005) 1.09

Visit-to-visit blood pressure variability in the European Lacidipine Study on Atherosclerosis: methodological aspects and effects of antihypertensive treatment. J Hypertens (2012) 1.09

Identification and management of the hypertensive patient with elevated heart rate: statement of a European Society of Hypertension Consensus Meeting. J Hypertens (2006) 1.09

Higher cardiovascular risk and impaired benefit of antihypertensive treatment in hypertensive patients requiring additional drugs on top of randomized therapy: is adding drugs always beneficial? J Hypertens (2012) 1.08

Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE). J Am Coll Cardiol (2004) 1.07

Cardiovascular target organ damage in essential hypertensives with or without reproducible nocturnal fall in blood pressure. J Hypertens (2004) 1.06

Blood pressure control in Italy: analysis of clinical data from 2005-2011 surveys on hypertension. J Hypertens (2012) 1.04

Prevalence and correlates of aortic root dilatation in patients with essential hypertension: relationship with cardiac and extracardiac target organ damage. J Hypertens (2006) 1.04

The relationship of waist circumference to blood pressure: the Olivetti Heart Study. Am J Hypertens (2002) 1.04

Lack of association between serum uric acid and organ damage in a never-treated essential hypertensive population at low prevalence of hyperuricemia. Am J Hypertens (2007) 1.02

International Society of Hypertension (ISH): statement on blood pressure lowering and stroke prevention. J Hypertens (2003) 1.02

Hypertensive myocardial fibrosis. Nephrol Dial Transplant (2005) 1.00

Short-term reproducibility of a non-dipping pattern in type 2 diabetic hypertensive patients. J Hypertens (2006) 0.98

Relationships between body mass index, cardiovascular mortality, and risk factors: a report from the SCORE investigators. Eur J Cardiovasc Prev Rehabil (2011) 0.98

The association between varicocele, premature ejaculation and prostatitis symptoms: possible mechanisms. J Sex Med (2009) 0.98

Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study. J Hypertens (2002) 0.97

Prevalence of type 2 diabetes among patients with hypertension under the care of 30 Italian clinics of hypertension: results of the (Iper)tensione and (dia)bete study. J Hypertens (2008) 0.96

Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial. J Hypertens (2006) 0.96

Age and target organ damage in essential hypertension: role of the metabolic syndrome. Am J Hypertens (2007) 0.95

Cardiovascular risk factors and dementia mortality: 40 years of follow-up in the Seven Countries Study. J Neurol Sci (2009) 0.95

The Study on COgnition and Prognosis in the Elderly (SCOPE) - major CV events and stroke in subgroups of patients. Blood Press (2005) 0.95

Blood pressure control in Italy: results of recent surveys on hypertension. J Hypertens (2007) 0.95

Effects of blood pressure lowering on outcome incidence in hypertension: 7. Effects of more vs. less intensive blood pressure lowering and different achieved blood pressure levels - updated overview and meta-analyses of randomized trials. J Hypertens (2016) 0.95

Total cholesterol and body mass index in relation to 40-year cancer mortality (the Corfu cohort of the seven countries study). Cancer Epidemiol Biomarkers Prev (2005) 0.94

Determinants of 40-year all-cause mortality in the European cohorts of the Seven Countries Study. Eur J Epidemiol (2011) 0.94

VALUE trial: Long-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk. Am J Hypertens (2003) 0.94

Retinal microvascular changes and target organ damage in untreated essential hypertensives. J Hypertens (2004) 0.93

The Study on COgnition and Prognosis in the Elderly (SCOPE); outcomes in patients not receiving add-on therapy after randomization. J Hypertens (2004) 0.93

Different effects of antihypertensive therapies based on losartan or atenolol on ultrasound and biochemical markers of myocardial fibrosis: results of a randomized trial. Circulation (2004) 0.93